Blood cytokines may hold key to predicting vitiligo progression
NCT ID NCT07298551
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study will measure 12 immune-signaling proteins (cytokines) in the blood of 125 people with vitiligo and healthy volunteers. The goal is to create a model that can predict when the disease will become active and how well a patient will respond to treatment. Currently, doctors rely on visible skin changes, which can be delayed and subjective. This research aims to provide an objective tool to guide earlier and more effective treatment decisions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this could lead to a simple blood test that helps doctors predict vitiligo flare-ups and choose the best treatment for each patient.
What could go wrong
This is an early observational study, not a treatment trial. The model may not prove accurate enough for routine use, and results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VITILIGO are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Xijing Hospital
Xi'an, Shannxi, 710032, China
Contact Phone: •••-•••-•••• Email: •••••@•••••